Ursodeoxycholic acid CAS 128-13-2 Market
Report ID: SQMIG35I3575
Report ID: SQMIG35I3575
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3575 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
118
|Figures:
77
Global Ursodeoxycholic Acid Cas 128-13-2 Market size was valued at USD 817.0 Million in 2024 and is poised to grow from USD 869.29 Million in 2025 to USD 1427.9 Million by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).
The global market for ursodeoxycholic acid (UDCA, CAS 128-13-2) revolves around its therapeutic application in treating cholestatic liver diseases such as primary biliary cholangitis and gallstone dissolution. Its primary driver is the rising prevalence of chronic liver disorders driven by aging populations and increasing metabolic syndrome rates worldwide. Historically, UDCA entered clinical use in the 1970s, but adoption accelerated after regulatory approvals in Europe and the United States in the early 2000s. Consequently, pharmaceutical manufacturers expanded production capacity, and generic versions entered the market, lowering cost barriers and spurring broader patient access to improve clinical outcomes globally and enhance quality. Another pivotal factor shaping the UDCA market is the expanding pipeline of combination therapies that leverage its hepatoprotective properties alongside emerging agents for non‑alcoholic fatty liver disease (NAFLD). As clinicians recognize that monotherapy often fails to halt disease progression, pharmaceutical firms are integrating UDCA with antifibrotic compounds, creating synergistic effects that improve liver enzyme normalization. This strategic shift has attracted substantial investment, evident in recent $150 million venture rounds funding joint development projects in Asia and Europe. The resulting clinical trials demonstrate reduced hospitalization rates for patients with advanced cholestasis, thereby generating an economic incentive for hospitals to adopt these regimens.
How is AI-driven drug discovery impacting the Ursodeoxycholic acid (CAS 128-13-2) market?
AI driven drug discovery is reshaping the Ursodeoxycholic acid market by accelerating target validation and streamlining synthetic design. Machine learning models can predict how subtle changes to the molecule affect solubility and bioavailability, allowing chemists to focus on the most promising candidates. This reduces laboratory cycles and shortens the time needed to bring new formulations to patients with liver disorders. Companies are integrating AI platforms with traditional fermentation processes to improve yield and lower production costs. As a result the pipeline for novel indications of Ursodiol is expanding while investors see greater confidence in the technology.Tanabe Pharma June 2026, employed AI to refine its Ursodiol synthesis route, cutting experimental steps and enhancing batch consistency. The streamlined process demonstrates how intelligent design can boost manufacturing efficiency and support broader market adoption of the compound while reducing time to clinical trial entry and enabling faster response to patient needs.
Market snapshot - (2026-2033)
Global Market Size
USD 817.0 Million
Largest Segment
Pharmaceutical Grade
Fastest Growth
Research Grade
Growth Rate
6.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global ursodeoxycholic acid cas 128-13-2 market is segmented by grade, form, application, end user and region. Based on grade, the market is segmented into Pharmaceutical Grade and Research Grade. Based on form, the market is segmented into API, Capsules, Tablets and Powder. Based on application, the market is segmented into Gallstone Treatment, Primary Biliary Cholangitis, Cholestatic Liver Diseases and Research Applications. Based on end user, the market is segmented into Pharmaceutical Companies, Hospitals and Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
API segment dominates because it serves as the foundational raw material that enables manufacturers to formulate a wide range of dosage forms, ensuring consistency and regulatory compliance. Its ability to meet stringent purity standards makes it indispensable for both generic and branded production, driving demand across therapeutic pipelines globally. Consequently, manufacturers prioritize securing reliable API supplies, cementing its central and strategic position firmly in the Ursodeoxycholic acid market.
However, Capsules segment emerges as the most rapidly expanding because oral solid dosage forms are gaining preference for patient convenience and adherence. Advances in encapsulation technology enable precise dosing and improved stability, attracting formulators seeking to differentiate their products. This growth fuels broader market reach and stimulates innovation across the Ursodeoxycholic acid landscape.
Gallstone Treatment segment dominates because it addresses the most common clinical indication for ursodeoxycholic acid, driving consistent demand from healthcare providers. The well established therapeutic efficacy builds physician confidence, which in turn supports reimbursement decisions and formulary inclusion across institutions, leading to sustained prescription volumes and encouraging manufacturers to prioritize production capacity for this indication. This entrenched usage ensures long term market stability and anchors the overall market trajectory.
Meanwhile, Primary Biliary Cholangitis segment is witnessing the strongest growth momentum because emerging clinical data highlight its benefits in slowing disease progression, prompting expanded prescribing beyond traditional indications. Increased awareness among hepatologists and supportive regulatory guidance encourage off label exploration, fostering new formulation development and opening additional revenue streams that accelerate market expansion.
To get detailed segments analysis, Request a Free Sample Report
Europe leadership in the global Ursodeoxycholic acid market is anchored by a confluence of mature regulatory environments, extensive clinical expertise, and a dense network of pharmaceutical manufacturers. The region benefits from harmonized approval pathways that streamline product introduction, while reimbursement frameworks ensure broad patient access. Strong academic collaborations drive continuous innovation and generate a pipeline of advanced formulations. Additionally, well‑established distribution channels and a focus on high‑quality manufacturing reinforce confidence among healthcare providers. These systemic strengths collectively sustain Europe’s dominant position and attract multinational investment.
Germany Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in Germany is supported by a robust pharmaceutical sector that emphasizes rigorous quality standards and advanced manufacturing capabilities. The country’s health system provides comprehensive coverage, facilitating patient uptake. Collaborative research institutions contribute to ongoing clinical studies, reinforcing therapeutic confidence. Strategic partnerships between local firms and global players further enhance market depth and ensure a steady supply of high‑grade product.
United Kingdom Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in the United Kingdom benefits from a well‑integrated healthcare framework that prioritizes evidence‑based therapies. National health services ensure equitable access, while regulatory bodies maintain stringent safety oversight. Strong academic networks drive clinical research, fostering continual refinement of treatment protocols. The presence of multinational pharmaceutical companies alongside innovative domestic firms creates a dynamic ecosystem that sustains market resilience and growth.
France Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in France is reinforced by a comprehensive reimbursement scheme that encourages widespread therapeutic use. The nation’s rigorous regulatory environment upholds product integrity, and leading research hospitals conduct pivotal clinical investigations. A mature manufacturing base, coupled with strategic collaborations across Europe, supports consistent product availability. These factors collectively nurture a stable market landscape and promote ongoing adoption.
North America’s rapid expansion of the Ursodeoxycholic acid market is driven by a combination of strong clinical demand, progressive reimbursement policies, and a vibrant ecosystem of biotech innovation. Healthcare providers increasingly recognize the therapeutic benefits, leading to broader prescribing practices. Payers are adopting favorable coverage decisions that reduce patient cost barriers. The United States and Canada host leading research institutions that continuously generate new clinical evidence, reinforcing confidence in the product. Moreover, a flexible regulatory environment accelerates product launches, while a well‑established distribution network ensures efficient market penetration across diverse care settings.
United States Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in the United States is propelled by extensive clinical adoption and a sophisticated payer landscape that supports reimbursement. Leading academic medical centers conduct ongoing research, expanding therapeutic indications. The presence of major pharmaceutical manufacturers ensures a reliable supply chain, while innovative biotech firms contribute novel delivery technologies. This confluence of clinical, financial, and manufacturing strengths sustains robust market activity.
Canada Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in Canada benefits from a universal health system that provides broad patient coverage, encouraging consistent utilization. Provincial health authorities prioritize evidence‑based therapies, facilitating swift formulary inclusion. Collaborative research programs between universities and hospitals generate valuable clinical data, reinforcing therapeutic confidence. Domestic manufacturers and international partners work together to maintain product quality and availability, supporting a stable market environment.
Asia Pacific is strengthening its position in the Ursodeoxycholic acid market through accelerated clinical integration, expanding healthcare infrastructure, and growing investment in pharmaceutical manufacturing. Nations such as Japan and South Korea prioritize advanced therapeutic options, leading to increased prescribing rates. Government initiatives that streamline regulatory approval and encourage domestic production enhance market accessibility. Strong ties between research institutions and industry foster continuous innovation, while rising patient awareness drives demand across the region.
Japan Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in Japan is underpinned by a highly organized healthcare system that emphasizes early adoption of effective therapies. National insurance schemes provide comprehensive coverage, facilitating patient access. Leading university hospitals conduct rigorous clinical trials, generating robust evidence for therapeutic use. Domestic manufacturers with advanced production capabilities ensure high‑quality supply, while strategic collaborations with global firms expand market reach and product diversity.
South Korea Ursodeoxycholic acid CAS 128-13-2 Market
Ursodeoxycholic acid CAS 128-13-2 Market in South Korea is supported by a proactive health policy framework that encourages rapid incorporation of innovative treatments. The national health insurance program offers extensive reimbursement, reducing financial obstacles for patients. Strong research institutions drive continuous clinical evaluation, enhancing confidence among prescribers. A growing domestic pharmaceutical sector, complemented by partnerships with international companies, secures a reliable pipeline of high‑standard product, reinforcing market growth.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness of Liver Disorders
Advancements in Formulation Technology
Regulatory Hurdles in Emerging Markets
High Cost Compared To Generics
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape for the global Ursodeoxycholic acid market is shaped by intensified rivalry among generic API manufacturers seeking to secure supply chains and meet rising demand for hepatobiliary therapies. Companies are pursuing strategic capacity expansions, forging partnerships with contract manufacturing organizations, and investing in biotechnological synthesis methods to lower production costs and differentiate product quality.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global Ursodeoxycholic acid market is being propelled primarily by rising awareness of cholestatic liver diseases, which is expanding physician prescribing and patient demand. A second catalyst is the rapid progress in formulation technology that improves bioavailability and enables new combination products, further widening the therapeutic footprint. The market faces a clear restraint in the form of stringent regulatory requirements in many emerging economies, slowing entry and raising development costs. Europe remains the dominant region, benefiting from mature approval pathways, strong reimbursement and a dense manufacturing base. Within the product landscape the API segment leads, providing the essential raw material for diverse dosage forms and anchoring overall market growth.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 817.0 Million |
| Market size value in 2033 | USD 1427.9 Million |
| Growth Rate | 6.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Ursodeoxycholic acid CAS 128-13-2 Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Ursodeoxycholic acid CAS 128-13-2 Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Ursodeoxycholic acid CAS 128-13-2 Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Ursodeoxycholic acid CAS 128-13-2 Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
